A.R.T. Advisors’s Plus Therapeutics PSTV Stock Holding History

A.R.T. Advisors’s Portfolio PSTV Stock Details PSTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-32	Closed	-$41K	–	1635
2019 Q3	$41K	Buy	+32	New	+$116K	﹤0.01%	1332

Other funds holding PSTV

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

EGM

Engineers Gate Manager New York $8B AUM 17.32% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

A.R.T. Advisors's PSTV Position: Q4 2019 in Review

A.R.T. Advisors sold out of Plus Therapeutics (PSTV) in Q4 2019, closing a stake of 32 shares — an estimated $41K sold.

A.R.T. Advisors first reported a position in PSTV in Q3 2019 and held it in 1 quarter. The position peaked at $41K in Q3 2019. 9 funds tracked by Wall St. Rank hold PSTV as of Q4 2019.

A.R.T. Advisors reported no remaining Plus Therapeutics position as of Q4 2019 after selling out during the quarter.
A.R.T. Advisors sold 32 Plus Therapeutics shares in Q4 2019, an estimated $41K.
A.R.T. Advisors first reported a position in Plus Therapeutics in Q3 2019 and held it in 1 quarter.
A.R.T. Advisors's Plus Therapeutics position peaked at $41K in Q3 2019.
9 funds tracked by Wall St. Rank held Plus Therapeutics as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.